Neutralization of human immunodeficiency virus type 1 (HIV-1) with antibody from carriers' plasma against HIV-1 protein p17.
It was investigated whether human antibody against HIV-1 protein p17 (anti-p17) in HIV carriers' plasma has the ability to neutralize the infectivity of HIV. By the pretreatment of HIV-1 with anti-p17 from HIV carriers, progeny HIV-1 production from cells infected with virus pretreated with anti-p17 was suppressed and/or delayed. The neutralizing activity of anti-p17 was decreased in the presence of recombinant p17. The latter obviously masked the neutralizing activity of anti-p17. The relevant epitope(s) on p17 is located apparently on the surface of HIV virions and the binding of anti-p17 to p17 impairs the infectivity of HIV. This implies that anti-p17, if stably present in HIV carriers' plasma, may also play an important role in reducing the infectivity of HIV-1 in vivo.
Kageyama
S
S
Department of Virology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Japan.
Katsumoto
T
T
Taniguchi
K
K
Ismail
S I
SI
Shimmen
T
T
Sasao
F
F
Gao
M
M
Owatari
S
S
Wakamiya
N
N
Tsuchie
H
H
Ueda
S
S
Shiraki
K
K
Kurimura
T
T
D000918:Antibody Specificity; D002353:Carrier State / Q000276:immunology*; D002461:Cell Line, Transformed; D015683:Gene Products, gag / Q000276:immunology*; D015483:HIV Antibodies / Q000097:blood / Q000276:immunology*; D015488:HIV Antigens / Q000276:immunology*; D006679:HIV Seropositivity / Q000097:blood / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000276:immunology* / Q000648:ultrastructure; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology; D009500:Neutralization Tests; D014407:Tumor Cells, Cultured; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus
D015683:Gene Products, gag; D015483:HIV Antibodies; D015488:HIV Antigens; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus; C054858:p17 protein, Human Immunodeficiency Virus Type 1